NasdaqGM - Nasdaq Real Time Price USD

Arcturus Therapeutics Holdings Inc. (ARCT)

12.65

+0.48

+(3.94%)

At close: April 23 at 4:00:00 PM EDT

12.65

0.00

(0.00%)

Pre-Market: 8:42:14 AM EDT

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

SAN DIEGO, April 22, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025.

Business Wire yesterday

ARCT
+3.94%
High Growth Tech Stocks To Watch In The US April 2025

As the U.S. market navigates a turbulent landscape marked by volatile trading sessions and fluctuating economic indicators, investors are closely watching the impact of ongoing tariff developments and bank earnings on major indices like the Dow Jones Industrial Average, which recently experienced significant swings. In such an environment, identifying high-growth tech stocks requires careful consideration of their resilience to macroeconomic pressures and potential for innovation amidst...

Simply Wall St. 12 days ago

BELFA

BELFB

DV
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate

The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.

Zacks 12 days ago

ARCT
+3.94%
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

SAN DIEGO, April 10, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, designed for active immunization to protect against disease c

Business Wire 14 days ago

ARCT
+3.94%
Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy?

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a look at where Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stands against other worst high-risk high-reward growth stocks to buy. Is the Tariff Solution Around the Corner? On March 14, Tom Lee managing partner […]

Insider Monkey last month

ARCT
+3.94%
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) missed earnings with its latest annual results, disappointing...

Simply Wall St. last month

ARCT
+3.94%
Q4 2024 Arcturus Therapeutics Holdings Inc Earnings Call

Q4 2024 Arcturus Therapeutics Holdings Inc Earnings Call

Thomson Reuters StreetEvents last month

ARCT
+3.94%
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ...

Despite a dip in revenue, Arcturus Therapeutics Holdings Inc (ARCT) focuses on innovation and strategic partnerships to bolster its pipeline and financial position.

GuruFocus.com last month

ARCT
+3.94%
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -226.47% and 60.60%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

ARCT
+3.94%
Arcturus Therapeutics: Q4 Earnings Snapshot

SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Thursday reported a loss of $30 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of $1.11. The pharmaceutical company posted revenue of $22.8 million in the period, which also fell short of Street forecasts.

Associated Press Finance last month

ARCT
+3.94%
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

SAN DIEGO, March 06, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2024, and provided corporate updates.

Business Wire last month

ARCT
+3.94%
Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

SAN DIEGO, March 05, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Leerink’s Global Healthcare Conference 2025 in Miami, on Wednesday, March 12, 2025, at 10:40 a.m. Eastern Time.

Business Wire last month

ARCT
+3.94%
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

SAN DIEGO, February 24, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2024 after the market close on Thursday, March 6 and will also host a conference call and webcast at 4:30 p.m. Eastern Time

Business Wire last month

ARCT
+3.94%
High Growth Tech Stocks In The United States To Watch

The United States market has shown a positive trajectory, climbing 1.5% in the past week and achieving a 22% increase over the last year, with earnings projected to grow by 15% annually in the coming years. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these expanding opportunities.

Simply Wall St. 2 months ago

ARCT
+3.94%
CAPR

IOVA
-0.62%
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE ® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission (EC). KOSTAIVE is currently marketed in Japan against COVID-19.

PR Newswire 2 months ago

CMXHF

CSLLY

ARCT
+3.94%
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?

Axsome (AXSM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 2 months ago

ARCT
+3.94%
AXSM
+0.39%
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

SAN DIEGO, February 04, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui, Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company’s Board of Directors since June 2024.

Business Wire 2 months ago

ARCT
+3.94%
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

TOKYO, January 31, 2025--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a partial amendment to the manufacturing and marketing approval of "KOSTAIVE® for Intramuscular Injection," a self-amplifying mRNA vaccine for protection against COVID-19, to include domestic manufacturing sites in Japan.

Business Wire 2 months ago

ARCT
+3.94%
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

SAN DIEGO, January 30, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Guggenheim Securities SMID Cap Biotech Conference in New York, on Thursday, February 6, 2025, at 10:30 a.m. Eastern Time.

Business Wire 2 months ago

ARCT
+3.94%
Arcturus Therapeutics launches Phase I Avian Influenza trials in US

The announcement follows just days after the US Centres for Disease Control confirmed its first death from the zoonotic disease.

Clinical Trials Arena 3 months ago

ARCT
+3.94%
GLDAF

Performance Overview

Return	ARCT	S&P 500 (^GSPC)
YTD	-25.46%	-8.60%
1-Year	-54.71%	+6.02%
3-Year	-40.50%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Arcturus Therapeutics Holdings Inc. (ARCT)

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

High Growth Tech Stocks To Watch In The US April 2025

Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Q4 2024 Arcturus Therapeutics Holdings Inc Earnings Call

Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ...

Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates

Arcturus Therapeutics: Q4 Earnings Snapshot

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

High Growth Tech Stocks In The United States To Watch

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

Arcturus Therapeutics launches Phase I Avian Influenza trials in US

Performance Overview